Siemens Healthcare Diagnostics Inc.

Siemens Healthcare Diagnostics Inc., a for-profit manufacturer and foreign-owned subsidiary of Siemens Aktiengesellschaft, sells in vitro diagnostic solutions, laboratory analyzers, reagents, and consumables to federal healthcare agencies as a prime contractor, competing exclusively on a full-and-open basis without set-aside protection. The company is headquartered in Tarrytown, New York, and operates across NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing) and 325414 (Analytical Laboratory Instrument Manufacturing), with primary PSC coding in laboratory equipment, diagnostic substances, and chemical analysis instruments.

Siemens Healthcare Diagnostics dominates federal laboratory diagnostic procurement. The top five customer agencies by potential value account for 62 percent of the $3.89 billion combined portfolio: the Department of Veterans Affairs Veterans Integrated Service Network 12 leads with $1.39 billion across 431 awards, followed by VISN 10 ($556.6 million, 445 awards), VISN 6 ($199 million, 229 awards), VISN 2 ($180.2 million, 246 awards), and VISN 22 ($95.6 million, 197 awards). The Indian Health Service places third by award count (720 awards, $84.8 million) but trails significantly by dollar value. Department of the Navy, Army Medical Command, and Defense Health Agency round out the active customer base. Concentration within the VA system is severe: Veterans Health Administration VISNs collectively account for over $2.3 billion of the $3.89 billion portfolio.

The Critical Analyzers, Laboratory Federal Supply Schedule (FSS-66-III), a GSA multiple-award vehicle, is Siemens' dominant vehicle footprint. The company holds 2,413 task orders under this schedule alone, worth $1.3 billion combined potential value. Secondary vehicles include Federal Supply Schedule V797P4767A (1,703 task orders, $257.8 million), V797P6580A (919 task orders, $23 million), and a $49 million single-award Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical through April 2030 for laboratory equipment and supplies to DoD and federal laboratories worldwide. Representative prime work includes a $3.7 million Defense Health Agency delivery order for chemistry analyzers (October 2025), $1.28 million to VISN 6 for chemistry immunoassay consumables and rental sealers (October 2025), a $945,965.55 Indian Health Service order for chemistry analyzer equipment and reportables in Albuquerque through September 2030 (November 2025), and a $738,203 VISN 6 BPA call for immunoassay chemistry system rental sealers and consumables (April 2026). The company also holds numerous single-award BPAs with individual VISNs: $564,832 with VISN 2 for blood gas testing (October 2026), $1.88 million with VISN 22 for blood gas analyzers and reagents through May 2031 (June 2026), and $3.13 million with VISN 2 for chemistry and immunochemistry testing and maintenance through September 2026 (October 2025).

Activity remains sustained but is moderating. Award volume peaked at 256 in 2022, declined to 202 in 2023, recovered to 210 in 2024 and 225 in 2025, then fell to 95 through October 2026. The source captures 8,427 total awards with 39 percent obligated ($1.51 billion of $3.89 billion potential value). Within the next twenty-four months, 112 awards with combined potential value of $46 million face ultimate completion and recompete exposure.

SCI-reportable federal service contract invoicing totaled $9 million across FY2022–FY2024, with $507 thousand in FY2022, $3.2 million in FY2023, and $5.2 million in FY2024. The dataset shows roughly 2.3 FTEs delivered to the federal government in FY2024 (versus 0.2 FTEs in FY2023). Median government-paid hourly rates on SCI-reportable prime contracts ran around $5,647/hr, with rates spanning $653/hr at the tenth percentile to $7,159/hr at the ninetieth percentile. Across SCI-reportable prime contracts, subcontractors performed approximately 2 percent of total hours, with only one named subcontractor reported, signaling that Siemens builds its own delivery teams and does not rely on extensive sub-engagement for service delivery. SCI figures represent a narrow slice of the vendor's federal revenue—the portfolio is overwhelmingly goods (analyzers, reagents, consumables) rather than billable service hours.

The vendor operates exclusively as a prime contractor on federal work; no sub-award footprint is present in the source. Siemens Healthcare Diagnostics competes across all customer agencies on full-and-open, unrestricted procurements without 8(a), HUBZone, SDVOSB, WOSB, or other set-aside designation. This reflects the vendor's foreign ownership status and position as an established, large-scale manufacturer without small-business eligibility.

Siemens Healthcare Diagnostics is a child of Siemens Medical Solutions Usa, Inc. (based in Malvern, Pennsylvania), which itself is a parent/child structure within the broader Siemens Aktiengesellschaft conglomerate. The subsidiary structure positions the company as a specialized diagnostics provider within the Siemens Healthineers division, enabling focused federal healthcare market engagement while leveraging parent company manufacturing scale and support infrastructure.